Immix Biopharma Subsidiary Nexcella Completes 2nd NXC-201 Engineering Batch At Its U.S. CAR-T Manufacturing Site
Portfolio Pulse from Benzinga Newsdesk
Immix Biopharma has announced the successful completion of its 2nd CAR-T NXC-201 engineering batch at its U.S. manufacturing site. This is a significant step in the planned U.S. expansion of the company's ongoing Phase 1b/2a NEXICART-1 study of its novel BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201. The company believes that NXC-201's observed zero neurotoxicity and favorable tolerability profile could enable expansion into earlier lines of therapy and out-patient NXC-201 dosing.
September 19, 2023 | 1:24 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Immix Biopharma's successful completion of its 2nd CAR-T NXC-201 engineering batch is a positive development for the company. This could potentially lead to the expansion of its ongoing NEXICART-1 study in the U.S., which would be beneficial for the company's growth.
The successful completion of the 2nd CAR-T NXC-201 engineering batch is a significant milestone for Immix Biopharma. This could potentially lead to the expansion of its ongoing NEXICART-1 study in the U.S., which would be beneficial for the company's growth. The company's belief that NXC-201's observed zero neurotoxicity and favorable tolerability profile could enable expansion into earlier lines of therapy and out-patient NXC-201 dosing is also a positive sign. This could potentially increase the company's market share and revenues in the future.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100